Clinical Efficacy with Relapsed Patients REBETRON™ Combination Therapy containing REBETOL® (Ribavirin, USP) Capsules and INTRON® A (Interferon alfa-2b, recombinant) Injection Achieves 46%* sustained virologic response in relapsers Sustained Loss of Detectable HCV RNA... 46% of patients (80/173) remained HCV-RNA negative at 24 weeks posttreatment† Comparative Virologic Response Rates: REBETRON Combination Therapy vs INTRON A Monotherapy *Combined results from two multicenter, randomized, double-blind studies of 345 chronic hepatitis C patients who relapsed after initial response to interferon therapy. Dosing regimen/duration: INTRON® A 3 MIU TIW plus either placebo or REBETOL® 1200 mg daily (1000 mg daily for patients weighing <75 kg) for 24 weeks of off-therapy follow-up. Results: Study 1 (n=153): Sustained virologic response in 33/77 REBETRON Combination Therapy patients vs. 3/76 INTRON A/placebo patients. Study 2 (n=192): Sustained virologic response in 46/96 REBETRON Combination Therapy patients vs. 5/96 INTRON A/placebo patients. † Defined as HCV RNA below limits of detection using a research-based RT-PCR assay at end of treatment and during follow-up period. ...Improves Liver Histology 63% of biopsied patients (88/139) showed histologic improvement vs. 41% of patients (58/138) receiving INTRON® A plus placebo ...And 94% of Patients (162/173) Completed the Entire Course of Treatment 7 of 11 Terms and Conditions | Privacy Policy | Important Safety Information